Dementia and subnormal levels of vitamin B12: Effects of replacement therapy on dementia

1996 ◽  
Vol 243 (7) ◽  
pp. 522-529 ◽  
Author(s):  
Saskia Teunisse ◽  
Anna E. Bollen ◽  
Willem A. van Gool ◽  
Gerard J.M. Walstra
Keyword(s):  
Vitamin B12 ◽  
Replacement Therapy

scholarly journals Hipotiroidismo primario, déficit de vitamina B12 y tiroiditis subaguda sobreagregada: informe de caso

2017 ◽  
Vol 2 (4) ◽  
pp. 51-54
Author(s):  
Carlos Alfonso Builes Barrera ◽  
María Gabriela García Orjuela
Keyword(s):  
Vitamin B12 ◽  
Replacement Therapy ◽  
Thyroid Disease ◽  
Vitamin B12 Deficiency ◽  
Primary Hypothyroidism ◽  
Subacute Thyroiditis ◽  
Normal Range ◽  
Hormonal Replacement ◽  
B12 Deficiency ◽  
Over Time

El hipotiroidismo primario es la patología tiroidea más frecuente. El manejo estándar de esta enfermedad es con levotiroxina, cuya absorción puede verse afectada por distintas condiciones médicas, medicamentos e incluso la dieta del paciente. Los requerimientos de levotiroxina podrían variar debido a factores sobre agregados como la tiroiditis subaguda, la deficiencia de vitamina B12 y el uso de medicamentos, elementos que afectan el control del hipotiroidismo. Se presenta el caso de una paciente con hipotiroidismo primario con necesidad de ajuste en la dosis de levotiroxina a través del tiempo debido a comorbilidades agregadas. Se presentan claves para la evaluación del paciente con dificultad para lograr una TSH dentro del rango normal.Abstract Hypothyroidism is the most common thyroid disease. This disease is managed with hormonal replacement therapy using levothyroxine, whose absorption can be affected by various medical conditions, drugs and even patient´s diet. Levothyroxine requirements could vary according to co-morbidities such as subacute thyroiditis, vitamin B12 deficiency and the use of drugs, factors that can affect the control of hypothyroidism. The case of a patient with primary hypothyroidism who required dose adjustments of levothyroxine over time due to added co-morbidities is presented. Clues are given for evaluation of the patient with difficulty in achieving maintenance of TSH within the normal range. 

Per oral vitamin B12 replacement therapy after gastrectomy and its optimal dose (retrospective study) and our protocol of a prospective clinical trial.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 338-338
Author(s):  
Yasushi Rino ◽  
Toru Aoyama ◽  
Norio Yukawa ◽  
Haruhiko Cho ◽  
Takashi Oshima ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Trial ◽  
Vitamin B12 ◽  
Replacement Therapy ◽  
Total Gastrectomy ◽  
Initial Treatment ◽  
Vitamin B12 Deficiency ◽  
Oral Vitamin ◽  
B12 Deficiency ◽  
Per Oral

338 Background: Postgastrectomy vitamin B12 deficiency is common metabolic sequel and worsens the quality of life of gastric cancer survivors. Recently, oral vitamin B12 replacement is reported. Therefore, we investigated retrospectively the efficacy of oral vitamin B12 replacement for gastric cancer patients with vitamin B12 deficiency after total gastrectomy. Methods: We reviewed 73 patients with gastric cancer who underwent total gastrectomy and were treated vitamin B12 replacement. Patients were consisted of 56 males and 17 females and median age was 70 y/o. We investigated initial treatment of vitamin B12 replacement and improvement of vitamin B12 deficiency. Results: Initial treatment of vitamin B12 replacements were intramuscular injection for 42 patients, per oral replacement for 28 patients and intravenous injection for 3 patients. Finally, all patients were treated with per oral replacement and the serum vitamin B12 levels became within normal range. Final vitamin B12 doses of replacement therapy were 500 µg of 20 out of 73 pts, respectively. Conclusions: Vitamin B12 replacement therapy should be necessary and continued. According to our results, one vitamin B12 tablet a day is enough. The vitamin B12 deficiency symptoms could be prevented. 500 micrograms vitamin B12 replacement orally is maybe effective and necessary. Our prospective clinical protocol (UMIN000030727): In this study, an oral vitamin B12 preparation (1500 μg/day, administered daily) was set as the control treatment, and a specific clinical trial was started to determine whether 500 μg/day daily administration would be sufficient for replacement therapy. Clinical trial information: UMIN000030727.

Sign in / Sign up

Export Citation Format

Share Document